National Cancer Institute
Found 8398 results for your search:
Total relevant funding to Cancer for this search:
$5,206,169,249
Fiscal Year FY 2016
Research Topic [Cancer]
Modify this Search New Search
Close

Modify Search Criteria

Some search criteria may be modified to refine your current search.

Select criteria to modify:

Add or remove search options:

Select criteria above to see additional search options

Cancel
Showing 1 - 50 of 8398 results
Clipboard
Project Title Sorted ascending Project Number Funded Amount
Relevant Funding
Principal
Investigator
Institution
1
(1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies 5P20CA192990-03 $171,681 $171,681 REAMS, ROMONIA FLORIDA AGRICULTURAL AND MECHANICAL UNIV
2
(1) Intestinal Organoid Models for APC LOH 1R21CA208638-01 $232,195 $232,195 GIARDINA, CHARLES UNIVERSITY OF CONNECTICUT STORRS
3
(1/2) University of Guam/University of Hawaii Cancer Center Partnership 5U54CA143727-07 $1,275,740 $1,275,740 PALAFOX, NEAL UNIVERSITY OF HAWAII AT MANOA
4
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients 1R21CA205636-01 $168,563 $168,563 CHEN, GRACE UNIVERSITY OF MICHIGAN
5
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities 5U54CA143930-07 $730,767 $730,767 FARIAS-EISNER, ROBIN UNIVERSITY OF CALIFORNIA LOS ANGELES
6
(2/2) Howard University/Johns Hopkins Partnership in HPV-Related Cancer Research 5P20CA192988-03 $184,939 $184,939 WU, TZYY-CHOOU JOHNS HOPKINS UNIVERSITY
7
(9) Biophysical Description of Age and Dose Dependent Changes to Dendritic Morphology that Impact Cognition following Radiation Cancer Therapy 1R01CA208526-01 $484,047 $484,047 CUCINOTTA, FRANCIS UNIVERSITY OF NEVADA LAS VEGAS
8
(ACN 12011-001-00004) FOR CBRG FOR THE CENTER FOR PROSTATE DISEASE RESEARCH ACN12011001 $459,666 $459,666 UNKNOWN, UNKNOWN UNIFORM THE SERVICES UNIVERSITY OF THE HEALTH
9
(NCI) Developing an Intermediate Energy Linac for Robotic Radiotherapy 3R43CA183390-01A1S1 $40,000 $40,000 BOUCHER, SALIME RADIABEAM TECHNOLOGIES, LLC
10
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblasto 5R01CA190121-03 $332,000 $332,000 VERHAAK, ROELAND UNIVERSITY OF TX MD ANDERSON CAN CTR
11
(PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors 1R21CA208723-01 $212,824 $212,824 BETTEGOWDA, CHETAN JOHNS HOPKINS UNIVERSITY
12
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation 1R01CA208535-01 $536,390 $536,390 GROSSHANS, DAVID UNIVERSITY OF TX MD ANDERSON CAN CTR
13
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer. 1R01CA206025-01 $655,037 $655,037 GUISE, THERESA INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
14
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers 1R01CA205258-01 $464,261 $464,261 GUDAS, LORRAINE WEILL MEDICAL COLL OF CORNELL UNIV
15
(PQ1) Epigenetic effects of the premalignant field 1R01CA208620-01 $357,464 $357,464 TERADA, LANCE UT SOUTHWESTERN MEDICAL CENTER
16
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS) 1R01CA205954-01 $438,499 $438,499 GHOBRIAL, IRENE DANA-FARBER CANCER INST
17
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation 1R01CA206026-01 $356,850 $356,850 WALDMAN, SCOTT THOMAS JEFFERSON UNIVERSITY
18
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer 1R01CA205608-01A1 $360,634 $360,634 SCHEET, PAUL UNIVERSITY OF TX MD ANDERSON CAN CTR
19
(PQ10) Do microbiota alter the epigenetic landscape in human genome 1R21CA208464-01 $254,475 $254,475 STRONGIN, ALEX SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
20
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy 1R21CA205644-01 $167,475 $167,475 WHITESIDE, THERESA UNIVERSITY OF PITTSBURGH AT PITTSBURGH
21
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer. 1R01CA208644-01 $377,438 $377,438 CRITTENDEN, MARKA PROVIDENCE PORTLAND MEDICAL CENTER
22
(PQ2) HIV INFECTION, APOBEC UPREGULATION, AND CANCER MUTAGENESIS 1R21CA206309-01 $219,289 $219,289 HARRIS, REUBEN UNIVERSITY OF MINNESOTA
23
(PQ3) AGEs and Race Specific Tumor Immune Response in Prostate Cancer 5R21CA194469-02 $140,445 $140,445 TURNER, DAVID MEDICAL UNIVERSITY OF SOUTH CAROLINA
24
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection 1R01CA206476-01 $772,521 $772,521 CHIAO, ELIZABETH BAYLOR COLLEGE OF MEDICINE
25
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer 1R01CA206010-01 $369,639 $369,639 CARETHERS, JOHN UNIVERSITY OF MICHIGAN
26
(PQ3) Modulation of Osteosarcoma Biology by Inflammation and Immunity Defined through a ComparativeApproach 1R21CA208529-01 $198,578 $198,578 MODIANO, JAIME UNIVERSITY OF MINNESOTA
27
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity 1R01CA208756-01 $518,165 $518,165 HACOHEN, NIR BROAD INSTITUTE, INC.
28
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years 1R01CA206477-01 $787,905 $787,905 PALEFSKY, JOEL UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
29
(PQ4) Elucidating Determinants of Susceptibility to Tumorigenesis in the Skin 1R21CA208298-01 $217,016 $217,016 RAMSEY, MATTHEW BRIGHAM AND WOMEN'S HOSPITAL
30
(PQ4) Mutations in the histone chaperone DAXX drive pancreatic neuroendocrine tumors not ductal adenocarcinomas 1R21CA208463-01 $208,800 $208,800 LOZANO, GUILLERMINA UNIVERSITY OF TX MD ANDERSON CAN CTR
31
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer 1R01CA206465-01 $563,374 $563,374 JUSTICE, AMY YALE UNIVERSITY
32
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression 3R01CA194461-02S1 $53,843 $53,843 PARK, KWON-SIK UNIVERSITY OF VIRGINIA
33
(PQ4A) Metabolic Plasticity of Pre-Malignant Cells During Tumor Progression 5R01CA194461-02 $340,050 $340,050 PARK, KWON-SIK UNIVERSITY OF VIRGINIA
34
(PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer 1R01CA208642-01 $352,275 $352,275 SHACKELFORD, DAVID UNIVERSITY OF CALIFORNIA LOS ANGELES
35
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity 1R01CA205967-01 $390,540 $390,540 LETAI, ANTHONY DANA-FARBER CANCER INST
36
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition 1R01CA206012-01 $417,457 $417,457 FACCIABENE, ANDREA UNIVERSITY OF PENNSYLVANIA
37
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression 1R01CA205975-01A1 $386,619 $386,619 GHAFFARI, SAGHI ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
38
(PQ5) Role of HIV-associated cellular miRNAs in HPV 16-induced pathogenesis 1R21CA206352-01 $237,750 $237,750 PALEFSKY, JOEL UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
39
(PQ5) Role of Mitochondrial Division in Cancer Biology 1R01CA206005-01 $351,209 $351,209 CHIPUK, JERRY ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
40
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer 1R01CA205632-01 $469,489 $469,489 RIEGEL, ANNA GEORGETOWN UNIVERSITY
41
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment 1R01CA205431-01 $533,945 $533,945 PERELMAN, LEV BETH ISRAEL DEACONESS MEDICAL CENTER
42
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity 1R01CA205101-01 $406,070 $406,070 SKALA, MELISSA MORGRIDGE INSTITUTE FOR RESEARCH, INC.
43
(PQ8) BONE MARROW-ON-A-CHIP"":AN INVITRO 3D MODEL OF BREAST CANCER DORMANCY 1R21CA208519-01 $165,844 $165,844 GEORGE, STEVEN WASHINGTON UNIVERSITY
44
(PQ9) A novel mechanism of paclitaxel-induced peripheral neuropathy and potential treatment 1R01CA208765-01 $351,874 $351,874 YANG, QING UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
45
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae 1R01CA208634-01 $560,277 $560,277 JURECIC, ROLAND UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
46
(PQ9) Dual Action RSK Inhibitor: Targeting Metastasis and Providing Cardioprotection 1R21CA208631-01 $251,120 $251,120 LANNIGAN, DEBORAH VANDERBILT UNIVERSITY MEDICAL CENTER
47
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy 1R01CA206028-01 $363,112 $363,112 GEWIRTZ, DAVID VIRGINIA COMMONWEALTH UNIVERSITY
48
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle 7R21CA205437-02 $152,333 $152,333 WANING, DAVID PENNSYLVANIA STATE UNIV HERSHEY MED CTR
49
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle. 1R21CA205437-01 $51,247 $51,247 WANING, DAVID INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
50
(PQ9) Prevention of Bleomycin-induced Pulmonary Toxicity by Dichloroacetate (DCA) 1R21CA208746-01 $198,485 $198,485 KIM, JUNG-WHAN UNIVERSITY OF TEXAS DALLAS
Total relevant funding to Cancer for this search: $5,206,169,249
Showing 1 - 50 of 8398 results
Go to top